Cornerstone Planning Group’s Acurx Pharmaceuticals ACXP Stock Holding History

Cornerstone Planning Group’s Portfolio ACXP Stock Details ACXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$245	Hold	167	–	–	﹤0.01%	1789
2026 Q1	$334	Hold	167	–	–	﹤0.01%	1728
2025 Q4	$433	Buy	167 +100	+149%	+$479	﹤0.01%	1536
2025 Q3	$5.29K	Buy	67 +59	+738%	+$356	﹤0.01%	934
2025 Q2	$850	Sell	8 -159	-95%	-$1.28K	﹤0.01%	1156
2025 Q1	$1.29K	Hold	167	–	–	﹤0.01%	1079
2024 Q4	$2.81K	Hold	167	–	–	﹤0.01%	702
2024 Q3	$6.49K	Hold	167	–	–	﹤0.01%	515
2024 Q2	$6.49K	Hold	167	–	–	﹤0.01%	519
2024 Q1	$7.26K	Hold	167	–	–	﹤0.01%	461
2023 Q4	$12.8K	Buy	+167	New	+$12.6K	﹤0.01%	388

Other funds holding ACXP

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

PFS

Prospect Financial Services Melville, New York $197M AUM 24.49% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

IWC

Integrated Wealth Concepts Waltham, Massachusetts $20.5B AUM 24.45% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

WIM

Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

Cornerstone Planning Group's ACXP Position: Q2 2026 in Review

Cornerstone Planning Group held its Acurx Pharmaceuticals (ACXP) position steady in Q2 2026 at 167 shares worth $245. The position accounts for ﹤0.01% of the portfolio, ranked #1789.

Cornerstone Planning Group first reported a position in ACXP in Q4 2023 and has held it in 11 quarters since. The position peaked at $12.8K in Q4 2023. 19 funds tracked by Wall St. Rank hold ACXP as of Q2 2026.

Cornerstone Planning Group held 167 shares of Acurx Pharmaceuticals worth $245 as of Q2 2026.
Cornerstone Planning Group left its Acurx Pharmaceuticals share count unchanged in Q2 2026.
Acurx Pharmaceuticals made up ﹤0.01% of Cornerstone Planning Group's portfolio in Q2 2026, its #1789 holding.
Cornerstone Planning Group first reported a position in Acurx Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
Cornerstone Planning Group's Acurx Pharmaceuticals position peaked at $12.8K in Q4 2023.
19 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q2 2026.

Based on Cornerstone Planning Group's 13F filing for Q2 2026, filed 29 Jul 2026.